Journal article icon

Journal article : Review

Crossing the finish line towards a disease-modifying treatment for Angelman syndrome

Abstract:
Recent progress in the development of genetic therapies promises that impactful treatments for single-gene neurodevelopmental disorders are imminent. But can derailed neurodevelopmental processes be mended after broken genes are replaced or otherwise restored? The results of ongoing clinical trials for Angelman syndrome will soon yield answers to this pressing question, yet the trials face significant obstacles. Here we identify insights needed to aid the quest for a disease-modifying Angelman syndrome therapy, which could serve as a roadmap for the expeditious development of genetic therapies for other single-gene neurodevelopmental disorders.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1186/s11689-026-09681-5

Authors


More from this funder
Funder identifier:
https://ror.org/01xxn5f34


Publisher:
BioMed Central
Journal:
Journal of Neurodevelopmental Disorders More from this journal
Volume:
18
Issue:
1
Article number:
15
Publication date:
2026-03-07
Acceptance date:
2026-02-23
DOI:
EISSN:
1866-1955
ISSN:
1866-1947


Language:
English
Keywords:
Subtype:
Review
Pubs id:
2392448
Local pid:
pubs:2392448
Source identifiers:
3868142
Deposit date:
2026-03-19
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP